AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6098034 — intervention group
Group type: COMPARATOR
Intervention: Single-dose cefotaxime (1 g im) plus probenicid (1 g orally)
Number of subjects: 20
Study 31222794 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocut
Number of subjects: 60
Study 31222794 — intervention group
Group type: COMPARATOR
Intervention: Autocut
Number of subjects: 60
Study 29052083 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific devices
Number of subjects: 0
Study 29052083 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27118495 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drainage autologous blood re-transfusion (ABT)
Number of subjects: 91
Study 27118495 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative vacuum drainage (Drain)
Number of subjects: 91
Study 24405258 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterforce brace 1
Number of subjects: 34
Study 24405258 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterforce brace 2
Number of subjects: 34
Study 24405258 — intervention group
Group type: COMPARATOR
Intervention: No brace (control)
Number of subjects: 34
Study 23160441 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily lens replacement each morning
Number of subjects: 215
Study 23160441 — intervention group
Group type: COMPARATOR
Intervention: Monthly lens replacement (historical control)
Number of subjects: 215
Study 20816284 — intervention group
Group type: EXPERIMENTAL
Intervention: Microimplant placement
Number of subjects: 28
Study 20816284 — intervention group
Group type: COMPARATOR
Intervention: Tooth extraction
Number of subjects: 28
Study 20816284 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgingival microimplant placement
Number of subjects: 28
Study 18245030 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 180
Study 18245030 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 180
Study 18245030 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation medication
Number of subjects: 180
Study 18245030 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from medication
Number of subjects: 180
Study 15736775 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone coverage
Number of subjects: 0
Study 15736775 — intervention group
Group type: COMPARATOR
Intervention: No coverage
Number of subjects: 0
Study 12762134 — intervention group
Group type: EXPERIMENTAL
Intervention: Talsaclidine (n = 34)
Number of subjects: 40
Study 12762134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 40
Study 12762134 — intervention group
Group type: EXPERIMENTAL
Intervention: Talsaclidine (n = 31)
Number of subjects: 40
Study 10835801 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach
Number of subjects: 22
Study 10835801 — intervention group
Group type: COMPARATOR
Intervention: Triflo-II
Number of subjects: 22
Study 8640420 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric film‐screen system
Number of subjects: 49
Study 8640420 — intervention group
Group type: COMPARATOR
Intervention: Conventional film‐screen system
Number of subjects: 49
Study 1451927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin (50 mg/kg in two equal doses each day for a mean of 10 days)
Number of subjects: 30
Study 1451927 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg in three equal doses each day for a mean of 11 days)
Number of subjects: 30
Study 4057139 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: local anaesthetic medially and laterally to the neurovascular bundle only
Number of subjects: 61
Study 4057139 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: local anaesthetic medially, laterally, and dorsally
Number of subjects: 61
Study 4057139 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 61
Study 30808022 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF (120 μg per putamen)
Number of subjects: 41
Study 30808022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 29980424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine supplementation
Number of subjects: 26
Study 29980424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 27093771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium perborate solution for 5 minutes per day combined with brushing
Number of subjects: 45
Study 27093771 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate solution for 5 minutes per day combined with brushing
Number of subjects: 45
Study 27093771 — intervention group
Group type: COMPARATOR
Intervention: Control group brushed with coconut soap and a soft toothbrush
Number of subjects: 45
Study 25410068 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia (7.5 mg hypobaric bupivacaine)
Number of subjects: 60
Study 25410068 — intervention group
Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia (12 mg hypobaric bupivacaine)
Number of subjects: 60
Study 21741471 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus a 45-min psychological intervention (relaxation and guided imagery) with take-home relaxation CDs for 3 days before and 7 days after surgery.
Number of subjects: 60
Study 21741471 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 60
Study 20484002 — intervention group
Group type: EXPERIMENTAL
Intervention: TeachTown: Basics (CAI program)
Number of subjects: 47
Study 20484002 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 18319308 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin treatment (EPT)
Number of subjects: 35
Study 18319308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15944847 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg o.d.)
Number of subjects: 349
Study 15944847 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (1,000/125 mg t.i.d.) plus roxithromycin (150 mg b.i.d.)
Number of subjects: 349
Study 12866746 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane 35 plus CPA (cyproterone acetate [2 mg] and ethinyl estradiol [35 microg])
Number of subjects: 79
Study 12866746 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane 35 plus spironolactone [100 mg]
Number of subjects: 79
Study 12866746 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone [100 mg] alone
Number of subjects: 79
Study 11299606 — intervention group
Group type: EXPERIMENTAL
Intervention: Database coverage for health sciences librarianship journals
Number of subjects: 0
Study 11299606 — intervention group
Group type: EXPERIMENTAL
Intervention: Search strategies for library literature
Number of subjects: 0
Study 11299606 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey literature of librarianship
Number of subjects: 0
Study 11299606 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems designed for tracking research evidence
Number of subjects: 0
Study 8803395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium alloy restorations
Number of subjects: 60
Study 1511371 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for colorectal cancer
Number of subjects: 0
Study 1511371 — intervention group
Group type: COMPARATOR
Intervention: Current screening guidelines of the American Cancer Society and the National Cancer Institute
Number of subjects: 0
Study 6821615 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 15
Study 6821615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30319467 — intervention group
Group type: EXPERIMENTAL
Intervention: 25, 40, or 55 h placement budgets (job coaches' time resources)
Number of subjects: 116
Study 30319467 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtaining a job
Number of subjects: 116
Study 27060174 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 1050
Study 26090941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Hydroxypropyl Methylcellulose/Dextran (HPMC/dextran)
Number of subjects: 70
Study 26090941 — intervention group
Group type: COMPARATOR
Intervention: 0.18% Sodium Hyaluronate (SH)
Number of subjects: 70
Study 23168373 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (8 g CHO per kg body mass)
Number of subjects: 22
Study 23168373 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate diet (3 g CHO per kg body mass)
Number of subjects: 22
Study 20880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg kg(‐1) in saline (20 mL)
Number of subjects: 110
Study 20880596 — intervention group
Group type: COMPARATOR
Intervention: Saline (20 mL)
Number of subjects: 110
Study 18854793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + Ketorolac (30 mg)
Number of subjects: 45
Study 18854793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + Ketorolac (30 mg) + Dexamethasone (8 mg)
Number of subjects: 45
Study 18854793 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (3 mg x kg‐1)
Number of subjects: 45
Study 16878206 — intervention group
Group type: COMPARATOR
Intervention: 50% silver nitrate (NIT)
Number of subjects: 30
Study 16878206 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% rhodamine B (ROD)
Number of subjects: 30
Study 16878206 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% methylene blue (MET)
Number of subjects: 30
Study 12499333 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (760 kcal)
Number of subjects: 25
Study 12499333 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate meal (isoenergetic)
Number of subjects: 25
Study 12499333 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with dietary antioxidants (865 kcal)
Number of subjects: 25
Study 10818325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 247
Study 10818325 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 247
Study 10818325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (patients over 50 years)
Number of subjects: 247
Study 10818325 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (patients over 50 years)
Number of subjects: 247
Study 8888436 — intervention group
Group type: EXPERIMENTAL
Intervention: SF 68 strain (150 x 10^6 CFU, three times a day for 5 days)
Number of subjects: 211
Study 8888436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 8888436 — intervention group
Group type: EXPERIMENTAL
Intervention: SF 68 strain
Number of subjects: 211
Study 1814322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (4, 2, or 1 mg) + Norethisterone acetate (1 mg)
Number of subjects: 2
Study 1814322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 mg) + Cyproterone acetate (1 mg) + Calcium (1000 mg)
Number of subjects: 2
Study 1814322 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol valerate + Cyproterone acetate without Calcium
Number of subjects: 2
Study 1814322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6359851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 to 240 mg)
Number of subjects: 365
Study 6359851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (5 to 10 mg)
Number of subjects: 365
Study 6359851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bendroflumethiazide and Nadolol (B + N)
Number of subjects: 365
Study 6359851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (25 to 100 mg twice daily)
Number of subjects: 365
Study 30896990 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Families Massachusetts)
Number of subjects: 704
Study 30896990 — intervention group
Group type: COMPARATOR
Intervention: Control group (referred to other services)
Number of subjects: 704
Study 28992526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetics-guided treatment
Number of subjects: 685
Study 28992526 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 685
Study 26559142 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐1st treatment (Selective laser trabeculoplasty)
Number of subjects: 718
Study 26559142 — intervention group
Group type: COMPARATOR
Intervention: Medicine‐1st treatment (IOP-lowering drops)
Number of subjects: 718
Study 23316850 — intervention group
Group type: EXPERIMENTAL
Intervention: High efficacy physical activity messages with high health risk information
Number of subjects: 611
Study 23316850 — intervention group
Group type: EXPERIMENTAL
Intervention: Low efficacy physical activity messages with high health risk information
Number of subjects: 611
Study 23316850 — intervention group
Group type: COMPARATOR
Intervention: Low efficacy physical activity messages with no health risk information
Number of subjects: 611
Study 23316850 — intervention group
Group type: COMPARATOR
Intervention: High efficacy physical activity messages with no health risk information
Number of subjects: 611
Study 21083685 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure attachment promotion programme (experimental group)
Number of subjects: 72
Study 21083685 — intervention group
Group type: COMPARATOR
Intervention: Educational talk (control group)
Number of subjects: 72
Study 19122308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home oxygen therapy (HOT)
Number of subjects: 20
Study 19122308 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-HOT)
Number of subjects: 20
Study 17031643 — intervention group
Group type: EXPERIMENTAL
Intervention: Doc-Gem (gemcitabine 900 mg/m² on days 1 and 8, docetaxel 75 mg/m² on day 1, every 3 weeks for up to six cycles)
Number of subjects: 113
Study 17031643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-Gem->Doc (gemcitabine 900 mg/m² on days 1 and 8, cisplatin 70 mg/m² on day 1 for three cycles, followed by docetaxel 100 mg/m² on day 1 for three cycles)
Number of subjects: 113
Study 15061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 262
Study 15061244 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 262
Study 11235929 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose = 3.8 mg)
Number of subjects: 50
Study 11235929 — intervention group
Group type: COMPARATOR
Intervention: Pimozide (mean daily dose = 2.9 mg)
Number of subjects: 50
Study 11235929 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 50
Study 11235929 — intervention group
Group type: COMPARATOR
Intervention: Pimozide
Number of subjects: 50
Study 11235929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 50
Study 9551840 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex partial seizures
Number of subjects: 0
Study 9551840 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondarily generalized seizures
Number of subjects: 0
Study 9551840 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 7577282 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall lift
Number of subjects: 25
Study 7577282 — intervention group
Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum
Number of subjects: 25
Study 2138925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 4129
Study 2138925 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment (Control)
Number of subjects: 4129
Study 2138925 — intervention group
Group type: EXPERIMENTAL
Intervention: First generation cephalosporins
Number of subjects: 4129
Study 2138925 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose regimens
Number of subjects: 4129
Study 638001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine
Number of subjects: 40
Study 638001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 40
Study 638001 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40
Study 638001 — intervention group
Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 40
Study 638001 — intervention group
Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 40
Study 31489495 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat strategy-based fitting (FSBF) maps
Number of subjects: 16
Study 31489495 — intervention group
Group type: COMPARATOR
Intervention: Fine-tuned clinical (FTC) maps
Number of subjects: 16
Study 31489495 — intervention group
Group type: COMPARATOR
Intervention: Single-channel fitting (SCF) maps
Number of subjects: 16
Study 25686338 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional intraoral alar base cinch suture (ABCS)
Number of subjects: 79
Study 25686338 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral ABCS
Number of subjects: 79
Study 25686338 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional ABCS plus an extra intraoral suture at points G.lat.
Number of subjects: 79
Study 25686338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 79
Study 23113663 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h 400‐calorie diet (fasting)
Number of subjects: 30
Study 23113663 — intervention group
Group type: COMPARATOR
Intervention: High‐calorie diet
Number of subjects: 30
Study 21520284 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (up to 50 U per eye)
Number of subjects: 109
Study 21520284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 19404210 — intervention group
Group type: EXPERIMENTAL
Intervention: XM02 (5 microg/kg/d, subcutaneous daily injections for at least 5 days and a maximum of 14 days)
Number of subjects: 240
Study 19404210 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim Neupogen (5 microg/kg/d, subcutaneous daily injections for at least 5 days and a maximum of 14 days)
Number of subjects: 240
Study 19404210 — intervention group
Group type: EXPERIMENTAL
Intervention: XM02
Number of subjects: 240
Study 16894934 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Glycyrrhizin for 6 months
Number of subjects: 40
Study 16894934 — intervention group
Group type: COMPARATOR
Intervention: HAART (Control)
Number of subjects: 40
Study 15147491 — intervention group
Group type: EXPERIMENTAL
Intervention: Name condition
Number of subjects: 96
Study 15147491 — intervention group
Group type: EXPERIMENTAL
Intervention: Function condition
Number of subjects: 96
Study 11453879 — intervention group
Group type: COMPARATOR
Intervention: Full dose heparinization (400 IU/kg) with standard uncoated ECC (Group A)
Number of subjects: 119
Study 11453879 — intervention group
Group type: COMPARATOR
Intervention: Full dose heparinization (400 IU/kg) with heparin-coated ECC (Group B)
Number of subjects: 119
Study 11453879 — intervention group
Group type: COMPARATOR
Intervention: Low dose heparinization (150 IU/kg) with heparin-coated ECC (Group C)
Number of subjects: 119
Study 11453879 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC with low dose systemic heparinization
Number of subjects: 119
Study 11453879 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 119
Study 9187181 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone imaging with I.V. 99mTc methylene diphosphonate
Number of subjects: 30
Study 1416135 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 30 micrograms/kg followed by propofol 2 mg/kg IV
Number of subjects: 75
Study 1416135 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 40 micrograms/kg followed by propofol 2 mg/kg IV
Number of subjects: 75
Study 1416135 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 50 micrograms/kg followed by propofol 2 mg/kg IV
Number of subjects: 75
Study 1416135 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 60 micrograms/kg followed by propofol 2 mg/kg IV
Number of subjects: 75
Study 1416135 — intervention group
Group type: COMPARATOR
Intervention: d‐tubocurarine 3 mg, thiamylal 4 mg/kg, and succinylcholine 1 mg/kg IV (Group I)
Number of subjects: 75
Study 4056246 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 9
Study 4056246 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 9
Study 4056246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31663290 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted (RA)
Number of subjects: 100
Study 31663290 — intervention group
Group type: COMPARATOR
Intervention: Conventional Open Fluoroscopic-Guided (FG)
Number of subjects: 100
Study 29782065 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 25 mcg
Number of subjects: 602
Study 29782065 — intervention group
Group type: COMPARATOR
Intervention: Foley catheterisation
Number of subjects: 602
Study 27617414 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 487
Study 27617414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 24954573 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 100
Study 24954573 — intervention group
Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 100
Study 24954573 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA) in obese patients
Number of subjects: 100
Study 24954573 — intervention group
Group type: COMPARATOR
Intervention: Right Radial Approach (RRA) in obese patients
Number of subjects: 100
Study 22809630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 30
Study 22809630 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 30
Study 22809630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Vildagliptin and Sitagliptin
Number of subjects: 30
Study 20226407 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecare Morcellex tissue morcellator
Number of subjects: 74
Study 20226407 — intervention group
Group type: COMPARATOR
Intervention: Rotocut G1 morcellator
Number of subjects: 74
Study 17585664 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency pulse plus auricular point magnetic therapy
Number of subjects: 50
Study 17585664 — intervention group
Group type: COMPARATOR
Intervention: Prepulsid
Number of subjects: 50